NCT04666038 2025-04-20BRUIN CLL-321Eli Lilly and CompanyPhase 3 Active not recruiting238 enrolled 17 charts 3 FDA
NCT01716806 2024-06-11A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)Seagen Inc.Phase 2 Completed131 enrolled 28 charts
NCT01874054 2019-02-12Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin LymphomaSeagen Inc.Phase 1/2 Completed55 enrolled 14 charts